Spots Global Cancer Trial Database for Simultaneous Gemcitabine and Irreversible Electroporation for Locally Advanced Pancreatic Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Simultaneous Gemcitabine and Irreversible Electroporation for Locally Advanced Pancreatic Cancer

Official Title: Simultaneous Gemcitabine and Irreversible Electroporation for Locally Advanced Pancreatic Cancer

Study ID: NCT02981719

Conditions

Pancreatic Cancer

Interventions

simultaneous gemcitabine and irreversible electroporation

irreversible electroporation

Study Description

Brief Summary: The aim of this study was to compare the therapeutic efficacy between simultaneous gemcitabine administration and IRE and IRE alone for locally advanced pancreatic cancer (LAPC)

Detailed Description: in the GEM- IRE group, before the IRE ablation started, patients received 1000 mg/m2 gemcitabine hydrochloride \[Qilu pharmaceutical (Hainan) Co., Ltd. Haikou, China\] intravenously (over approximately 30 min). In the IRE group, the IRE ablation was performed without gemcitabine intravenous infusion before IRE. The aim of this study was to evslusted the overall survival (OS), objective response rate (ORR) and adverse events after simultaneous therapy.